ETS transcription factors from the ERG and ETV1/4/5 subfamilies are overexpressed in the majority of prostate cancer patients and contribute to disease progression. Here, we develop two in vitro assays for the interaction of ETS transcription factors with DNA that are amenable for high throughput screening. Using ETS1 as a model, these assays were applied to screen 110 compounds derived from a high-throughput virtual screen. We find that the use of lower affinity DNA-binding sequences, similar to those which ERG and ETV1 bind to in prostate cells, allowed for higher inhibition from many of these test compounds. Further pilot experiments demonstrated that the in vitro assays are robust for ERG, ETV1, and ETV5, three of the ETS transcription factors that are overexpressed in prostate cancer.
are recent examples demonstrating successful modulation of transcription factor activity through the inhibition of protein-protein and protein-DNA interfaces. [2] [3] [4] [5] The ETS family of transcription factors contains 28 human genes that have a conserved ETS DNA-binding domain (Fig. 1A) . Factors of the ERG (ERG, FLI1, FEV) and ETV1/4/5 (ETV1, ETV4, ETV5) subfamilies are involved in chromosomal rearrangements that result in the overexpression of one of these proteins in the majority of prostate cancer patients. 6 Preclinical modeling of prostate cancer suggests that the overexpression of ERG, ETV1, or ETV4 contributes to further disease progression, indicating that these transcription factors are desirable therapeutic targets. [7] [8] Here we have designed in-vitro DNA-binding assays for ETS transcription factors that are amenable to high-throughput screening. We piloted these assays using ETS1 and a library of 110 compounds derived from high-throughput virtual screening. Furthermore, we demonstrate that using lower affinity ETS DNA binding sites, similar to those bound by ERG and ETV1 in prostate cancer cells, raises the efficacy of inhibitors of ETS-DNA interactions. Finally, we establish that these in vitro assays can be used with the prostate cancer relevant ETS factors ERG, ETV1, and ETV5.
Materials and Methods

DNA Constructs
Human cDNAs corresponding to full-length ETV1, ETV5, and ERG were cloned into the bacterial expression vector pET28 (Novagen) using standard sequence and ligation independent cloning strategies as previously described. 9 ETS1 Δ N279 construct in pET28 was cloned as previously described. 10
Expression and Purification of Proteins
All proteins were produced in Escherichia coli (λDE3) cells. ETS1 Δ N279 efficiently expressed into the soluble fraction. Cultures of 1 L Luria broth (LB) were grown at 37 °C to OD 600 ~ 0.7 -0.9, induced with 1 mM isopropyl-β-Dthiogalactopyranoside (IPTG), and grown at 30 °C for ~ 3 hours.
Harvested cells were resuspended in 25 mM Tris pH 7.9, 1 M NaCl, 5 mM imidazole, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 2 mM 2mercaptoethanol (βME), and 1 mM phenylmethanesulfonylfluoride (PMSF). Cells were lysed by sonication and centrifuged at 40k rpm in a Ti-45 rotor (Beckmann) for at least 30 minutes at 4 °C. After centrifugation, the soluble supernatants were loaded onto a Ni 2+ affinity column (GE Biosciences) and eluted over a 5-500 mM imidazole gradient. Fractions containing purified protein were pooled and dialyzed overnight at 4 °C into 25 mM Tris pH 7.9, 10% glycerol (v:v), 1mM EDTA, 50 mM KCl, and 1 mM dithiothreitol (DTT). After centrifugation at 40k rpm (Ti-45 rotor) for 30 minutes at 4 °C, the soluble fraction was loaded onto a SP sepharose cation exchange column (GE Biosciences) and eluted over a 50-1000 mM KCl gradient. Fractions containing the ETS proteins were loaded onto a Superdex 75 gel filtration column (GE Biosciences) and eluted fractions were analyzed by SDS-PAGE for purified ETS proteins. The final, purified protein was then concentrated on a 10-kDa molecular weight cut-off (MWCO) Centricon device, snap-frozen in liquid nitrogen, and stored at -80°C in single-use aliquots for subsequent in vitro studies.
Full-length ERG, ETV1, and ETV5 generally expressed more efficiently in the insoluble fraction using IPTG induction as described above. Harvested cells were resuspended as described above, sonicated and centrifuged at 15k rpm for 15 min at 4 °C. The soluble fraction was discarded and this procedure was repeated with the pellet / insoluble fraction twice more to rinse the inclusion bodies. The final insoluble fraction was resuspended with 25 mM Tris pH 7.9, 1 M NaCl, 0.1 mM EDTA, 5 mM imidazole, 2 mM BME, 1 mM PMSF, and 6 M urea. After sonication and incubation for ~ 1 hr at 4 °C, the sample was centrifuged for 40k rpm for at least 30 min at 4 °C. The soluble fraction was loaded onto a Ni 2+ NTA affinity column (GE Biosciences) and refolded by immediately switching to a buffer with the same components as above except lacking urea. After elution with 5 to 500 mM imidazole, the remaining purification steps, ion-exchange and size-exclusion chromatography, were performed as described above. However, a Q sepharose anion-exchange column was used instead of a SP sepharose cation-exchange column due to differing isoelectric points of the full-length proteins compared to ETS1 Δ N279.
Protein concentrations were measured using averages from the following two methods after ensuring that the concentrations from each method were in agreement with one another (within ~ 2 fold). SynergySoftware). Due to the low concentration of total DNA, [D] t , in all reactions, the total protein concentration is a valid approximation of the free, unbound protein concentration.
Electrophoretic Mobility Shift Assays
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Computational Methods
Computational methods were used as previously described. 12 All computational studies used PDB ID 2NNY for the structural coordinates of ETS1. 13 PocketFinder (ICM) and SiteMap (Schrödinger) were used to define ligandbinding sites. Out of the three ETS1 protein and one DNA ligand-binding sites that were defined by PocketFinder and SiteMap, only ETS1 site 1 was used for docking studies. In sum, this process resulted in 110 compounds that were purchased and screened using the in vitro ETS1-DNA binding assays.
Fluorescence Polarization
Fluorescence polarization reactions were performed in the same buffer as described above for EMSAs. SC1 DNA was ordered with a 3' fluorescein.
Reactions were carried out in 20 μ L volumes in black 384 well plates (Corning).
The protein, DNA, and compound were incubated for 30 min at room temperature, protected from light. Timecourse studies demonstrated that less than 5 min were required for the protein-DNA reaction to reach equilibrium;
however, we went with a longer incubation time to encourage compoundprotein interactions, potentially with significantly lower affinity and kinetics, to also reach equilibrium. Reactions containing up to 5% DMSO showed no influence on 
Comparison of Fluorescence Polarization and ALPHAScreen Assays
Equation (2) was used to compare the assay performance between fluorescence polarization and ALPHAScreen assays for ETS1 (μ and σ are mean and standard deviation and c+ and c-are positive and negative controls). 14
Results and Discussion
ETS1
Δ N279 (residues 279 -441) was used to pilot in vitro assays that could be utilized for high-throughput screening of potential small molecule inhibitors of ETS-DNA interactions. This fragment has robust expression in a recombinant system and contains the same affinity for DNA as full-length ETS1. 10 The ETS domains of ETS1, ERG, and ETV1 are sequentially and structurally conserved ( Fig. 1A and Suppl. Fig. S1A) . Therefore, ETS1 serves as a good model for the DNA binding of these other ETS factors, and inhibitors that prevent ETS1 from binding to DNA would likely also inhibit ERG and ETV1.
Δ N279 was expressed in E. coli and purified using a Ni 2+ affinity column, a cation exchange column, and a size exclusion column (Suppl. Fig.   S1B ). Using electrophoretic mobility shift assay (EMSA) we measured the binding of ETS1 Δ N279 to DNA with a consensus ETS site (5'-CCGGAAGT-3'), termed SC1 (Selected Clone 1). 11 The measured K D of 0.4 nM is in agreement with previous measurements for this fragment binding to DNA (Suppl. Fig.   S1C ). 10 The yield of ETS1 Δ N279 showed a dosedependent response in these two assays with a concentration of around 30-50 nM generating maximum signal (Fig. 1B,C) . Based on these titrations, 10 nm concentrations of ETS1 Δ N279 were used in the fluorescence polarization and ALPHAScreen assays for compound screening studies. The maximum signal and the baseline were used to calculate a Z' factor for these assays. The fluorescence polarization assay had a Z' factor of 0.4 and the ALPHAScreen assay had a Z' factor of 0.7. Z' factors above 0.5 are considered to be excellent assays for high-throughput screening purposes. 14 
Whereas the ETS1
ALPHAScreen assay already clears this guideline, the ETS1 fluorescence polarization assay is close and could likely be optimized to achieve Z' factors over 0.5.
Computer modeling was utilized to enrich for likely bioactive compounds to be screened using these newly established in-vitro assays. Briefly, PocketFinder (ICM) and SiteMap (Schrodinger) were used to define ligandbinding pockets in the ETS domain of ETS1 (Suppl. Fig. 2) . Sequential rounds of virtual screening using one of these defined ligand-binding pockets, termed ETS1 site 1, culled a starting library of 13 million compounds down to 110 compounds to be tested in the in-vitro ETS1 DNA binding assays. In addition to the predicted strength of interaction with ETS1, these compounds were also filtered to optimize chemical diversity and enrich for compounds with favorable physicochemical properties.
A constant concentration of protein and DNA, as indicated above, was used to test the inhibition of each of the 110 compounds that resulted from virtual screening. These compounds were tested at a single concentration of 60 μ M and each compound or control was measured in quadruplicates. Using three standard deviations above the baseline (3-SD) as a cutoff, only two compounds in the fluorescence polarization assay, and four compounds in the ALPHAScreen assay, respectively, inhibited the ETS1 Δ N279-DNA interaction. Only one of these compounds inhibited this interaction in both assays ( Fig. 2A) .
To further investigate these compounds, as well as some additional compounds that were close to the 3-SD cutoff, we utilized the 'TruHits' false positive screen in ALPHAScreen. In this assay a small molecule that covalentlyconjugates biotin and His 6 together is used in lieu of the biomolecules of interest, in this case ETS1 Δ N279 and SC1 DNA. Compounds that inhibit the false positive assay do so through a manner inherent to the assay itself such as by absorbing light in the donor or emission wavelengths or by disrupting the streptavidin-biotin or His 6 -Ni 2+ interactions that conjugate the biomolecules to the ALPHA beads. All of the compounds that strongly inhibited the ALPHAScreen assay also strongly inhibited this false positive assay (Fig 2B) . Only two compounds that had weak to moderate inhibition of the ALPHAScreen assay displayed differential preference for inhibiting the ALPHAScreen assay more robustly than the false positive assay.
With very few, if any, actual hits from our first round of in vitro screening we next considered potential adjustments to our assays. One potential challenge with this screen is that the strength of the ETS1 Δ N279-SC1 DNA interaction (K D = 0.4 nM) might conceal the discovery of starting compounds with relatively lower affinity for ETS1 Δ N279, which then could be further optimized for inhibition. To address this we switched from SC1 (5'-GCCGGAAGTG-3'), the highest affinity DNA sequence for ETS1, to a weaker ETS1 binding sequence, SC13 (5'-ACAGGATATC-3'). By EMSA, ETS1 Δ N279 bound to SC13 with K D of 3 nM (data not shown). This roughly tenfold weaker interaction is consistent with the difference observed between SC1 and SC13 DNA with other ETS1 truncations. 11 We rescreened the 110 compounds against ETS1 and SC13 DNA.
Eighteen of these compounds inhibited the ETS1-SC13 interaction above the 3-SD cutoff, as compared to only four for the ETS1-SC1 interaction (Fig. 3A) .
While many of these compounds still inhibited the 'TruHits' false positive assay, 12/20 compounds showed more inhibition in the ETS1-SC13 assay than the false positive assay (Fig. 3B) , compared to only 2/12 compounds that showed more inhibition in the ETS1-SC1 assay than the false positive assay (Fig. 2B) .
Therefore, using the weaker interaction of ETS1 with SC13 DNA enabled higher disrupt of the ETS1-DNA interaction by compounds. Additionally, a significant part of the inhibition observed in the ALPHAScreen assays for most of these compounds appears to come from "off-target" effects in the assay, besides
interrupting the ETS-DNA interaction. However, as several of these compounds display stronger inhibition of the ETS1-SC13 assay than the false positive assay, these compounds may inhibit the ETS1-DNA interaction in addition to the ALPHAScreen assay in general.
In both the ETS1-SC1 and ETS1-SC13 screens the same compound, CIT-0312, displayed the largest differential between inhibition of ETS1 transcription factors from binding to their cognate DNA recognition sites (Data not shown). Therefore, this particular compound must be inhibiting the DNA binding of ETS1, as well as other transcription factors, through a non-specific mechanism that is distinct from the prediction of our in silico modeling (Suppl. Fig. 2) .
Within the ETS family of transcription factors, ERG and ETV1/4/5 subfamily proteins are overexpressed in prostate cancer and contribute to disease progression, making therapeutic inhibition of these proteins desirable. [7] [8] To establish that the screening assays used here for ETS1 are also suitable for these oncogenic proteins we expressed and purified full length, His 6 -tagged ERG, ETV1, and ETV5. Titrations of these proteins with 10 nM of biotin-tagged SC13 DNA and streptavidin donor and nickel chelate acceptor beads established that these proteins similarly generate robust ALPHAScreen signal, with a maximum signal observed around 20-70 nM, depending on the individual protein ( Fig. 4) . Each of these interactions had Z' factors over 0.5 (ERG, 0.8; ETV1, 0.6; ETV5, 0.8) suggesting that they would be suitable for high-throughput screening.
In summary we have established two in vitro assays, ALPHAScreen and fluorescence polarization, that are suitable for high-throughput screening of potential small molecule inhibitors of ETS-DNA interactions. Using weaker affinity DNA, such as SC13, was advantageous for more readily identifying potential lead compounds from the screens. Interestingly, these weaker affinity DNA sites may also be more biologically relevant as they more closely resemble the ERG and ETV1 DNA-binding sites that are relevant in prostate cancer. [7] [8] In contrast, consensus ETS sites, such as SC1, are redundantly regulated by multiple ETS factors and control the expression of housekeeping genes. 15 These in vitro assays are suitable for ETS factors with high clinical relevance, such as ERG and ETV1, and can be used for performing high-throughput screens of these factors. Furthermore, as directly inhibiting transcription factor-DNA interactions remains a difficult target, 1 these assays could also be used to screen for compounds that inhibit the function of ETS factors through alternative mechanisms. For instance, screens could conducted for small molecules that reinforce the diverse autoinhibitory mechanisms of ETS factors. 9 Alternatively, these assays could be readily modified to search for disruptors of protein-protein interactions between ETS factors and important transcriptional coregulators. 
